Mersana Therapeutics MRSN

$ 1.81 -3.21%

Quarterly report 2024-Q2
added 08-13-2024

Mersana Therapeutics Balance Sheet 2011-2024 | MRSN

Annual Balance Sheet Mersana Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-148 M	-101 M	-151 M	-249 M	-57.5 M	-59.6 M	-26.6 M	-100 M	-11.5 M	-	-	-	-
Long Term Debt	23.1 M	24.9 M	24.6 M	4.98 M	4.2 M	-	-	-	-	-	-	-	-
Long Term Debt Current	3.25 M	2.8 M	2.3 M	1.44 M	2.22 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	5.15 M	282 K	28.8 M	132 M	46.4 M	-	-	-	-
Total Current Liabilities	63.6 M	91.5 M	47.5 M	30 M	24.1 M	69.4 M	31.9 M	-	-	-	-	-	-
Total Liabilities	189 M	242 M	84.4 M	45.3 M	29.2 M	69.7 M	60.7 M	161 M	57.1 M	-	-	-	-
Deferred Revenue	28.1 M	30.6 M	3.94 M	3.99 M	4.82 M	46.2 M	21.6 M	22.7 M	7.05 M	-	-	-	-
Retained Earnings	-826 M	-655 M	-450 M	-280 M	-192 M	-164 M	-97.9 M	-59.2 M	-45.5 M	-	-	-	-
Total Assets	226 M	334 M	206 M	273 M	108 M	78.5 M	131 M	105 M	14.4 M	-	-	-	-
Cash and Cash Equivalents	175 M	129 M	178 M	255 M	62.4 M	59.6 M	26.6 M	100 M	-	-	-	-	-
Book Value	36.9 M	92.1 M	122 M	228 M	78.3 M	8.8 M	70 M	-55.6 M	-42.7 M	-	-	-	-
Total Shareholders Equity	36.9 M	92.1 M	122 M	228 M	78.3 M	8.8 M	70 M	-55.6 M	-42.7 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Mersana Therapeutics

	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	17 M	23.1 M	25 M	25 M	25 M	24.9 M	25 M	25 M	25 M	24.6 M	5.2 M	5.03 M	5.2 M	4.98 M	4.94 M	3.26 M	3.73 M	4.2 M	4.2 M	4.2 M	4.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	171 M	189 M	211 M	221 M	232 M	242 M	225 M	118 M	118 M	84.4 M	62 M	58.2 M	50 M	45.3 M	45.3 M	45.3 M	45.3 M	29.2 M	29.2 M	29.2 M	29.2 M	69.7 M	69.7 M	69.7 M	69.7 M	60.7 M	60.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	29.3 M	28.1 M	21.6 M	20.5 M	28.8 M	30.6 M	30.9 M	26.2 M	16.6 M	3.94 M	3.96 M	3.97 M	3.98 M	3.99 M	3.99 M	3.99 M	3.99 M	4.82 M	4.82 M	4.82 M	4.82 M	46.2 M	46.2 M	46.2 M	46.2 M	21.6 M	16.5 M	24.9 M	21.6 M	22.7 M	22.7 M	22.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-870 M	-826 M	-807 M	-765 M	-711 M	-655 M	-610 M	-550 M	-498 M	-450 M	-401 M	-356 M	-315 M	-280 M	-280 M	-280 M	-280 M	-192 M	-192 M	-192 M	-192 M	-164 M	-164 M	-164 M	-164 M	-97.9 M	-97.9 M	-97.9 M	-97.9 M	-59.2 M	-59.2 M	-59.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	179 M	226 M	263 M	311 M	296 M	334 M	315 M	252 M	258 M	206 M	218 M	254 M	248 M	273 M	273 M	273 M	273 M	108 M	108 M	108 M	108 M	78.5 M	78.5 M	78.5 M	78.5 M	131 M	131 M	131 M	131 M	105 M	105 M	105 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	59 M	175 M	186 M	129 M	123 M	129 M	184 M	135 M	230 M	178 M	192 M	227 M	228 M	255 M	255 M	255 M	255 M	62.4 M	62.4 M	62.4 M	62.4 M	59.6 M	59.6 M	59.6 M	59.6 M	26.6 M	26.6 M	26.6 M	26.6 M	100 M	100 M	100 M	-	11.5 M	-	-	-	12 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	8.43 M	36.9 M	52.2 M	89.8 M	64.3 M	92.1 M	90.2 M	134 M	141 M	122 M	156 M	196 M	198 M	228 M	228 M	228 M	228 M	78.3 M	78.3 M	78.3 M	78.3 M	8.8 M	8.8 M	8.8 M	8.8 M	70 M	70 M	131 M	131 M	105 M	105 M	105 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	8.43 M	36.9 M	52.2 M	89.8 M	64.3 M	92.1 M	90.2 M	134 M	141 M	122 M	156 M	196 M	198 M	228 M	228 M	228 M	228 M	78.3 M	78.3 M	78.3 M	78.3 M	8.8 M	8.8 M	8.8 M	8.8 M	70 M	70 M	70 M	70 M	-55.6 M	-55.6 M	-55.6 M	-	-42.7 M	-	-	-	-26.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency